<DOC>
	<DOCNO>NCT03099200</DOCNO>
	<brief_summary>The purpose study compare productivity ( term work daily activity ) generic disease-specific health-related quality life participant HER2 positive early breast cancer currently receive adjuvant treatment ( chemotherapy and/or target HER2 therapy ) , participant complete adjuvant parenteral therapy , participant HER2 positive metastatic breast cancer .</brief_summary>
	<brief_title>An Observational Study Evaluating Productivity Health-Related Quality Life People With HER2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Diagnosed early stage metastatic ( Stage IV ) HER2positive breast cancer ( confirm study site physician ) . [ HER2positive define ImmunoHistoChemistry ( IHC3+ ) and/or situ hybridization ( ISH ) ≥2.0 ] Able provide write , informed consent . Early Stage Breast Cancer ( eBC ) patient must receive least 1 cycle adjuvant anticancer therapy follow surgery ; metastatic breast cancer ( mBC ) patient must receive least 1 cycle treatment metastatic disease . Unwilling unable consent . Unable complete write quality life questionnaires Partcipants Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≥3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>